Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -422412.50% is 1727% below its 1-year average of -23117.50%, near the low end of its 1-year range (-422412.50%–0.00%).
1727.24% below its 12-month average of -23117.50%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
NET PROFIT MARGIN
-422412.50%
NET PROFIT MARGIN AVG TTM
-23117.50%
NET PROFIT MARGIN AVG 3Y
0.00%
NET PROFIT MARGIN AVG 5Y
0.00%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-1727.24%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.06%
median of 853 covered companies
CURRENT VS SECTOR MEDIAN
-704020733.33%
vs the sector median at left
Genelux Corporation
Market Cap
$114.57M
Net Profit Margin
-422412.50%
TTM Avg
-23117.50%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$114.55M
Net Profit Margin
-1030.42%
TTM Avg
-1409.68%
3Y Avg
-958.30%
5Y Avg
-801.33%
Market Cap
$114.27M
Net Profit Margin
-959.76%
TTM Avg
-1140.14%
3Y Avg
-4837.22%
5Y Avg
-4160.74%
Market Cap
$113.01M
Net Profit Margin
-114.77%
TTM Avg
-120.72%
3Y Avg
-96.63%
5Y Avg
-81.33%
Market Cap
$112.81M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
-1605.97%
5Y Avg
-1070.65%
Market Cap
$112.53M
Net Profit Margin
-2955.63%
TTM Avg
-2231.78%
3Y Avg
-3480.44%
5Y Avg
-3216.57%
Market Cap
$116.70M
Net Profit Margin
-270.22%
TTM Avg
-342.92%
3Y Avg
-204.73%
5Y Avg
-136.49%
Market Cap
$111.92M
Net Profit Margin
-175.78%
TTM Avg
-311.79%
3Y Avg
-369.50%
5Y Avg
-4193.27%
Market Cap
$117.36M
Net Profit Margin
-52.59%
TTM Avg
-29.17%
3Y Avg
-18.36%
5Y Avg
-9.63%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Genelux Corporation (GNLX) | $114.57M | -422412.50% | -23117.50% | 0.00% | 0.00% |
| Caribou Biosciences, Inc. (CRBU)vs › | $114.55M | -1030.42% | -1409.68% | -958.30% | -801.33% |
| Lucid Diagnostics Inc. (LUCD)vs › | $114.27M | -959.76% | -1140.14% | -4837.22% | -4160.74% |
| MaxCyte, Inc. (MXCT)vs › | $113.01M | -114.77% | -120.72% | -96.63% | -81.33% |
| Unicycive Therapeutics, Inc. (UNCY)vs › | $112.81M | 0.00% | 0.00% | -1605.97% | -1070.65% |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $112.53M | -2955.63% | -2231.78% | -3480.44% | -3216.57% |
| Coya Therapeutics, Inc. (COYA)vs › | $116.70M | -270.22% | -342.92% | -204.73% | -136.49% |
| Foghorn Therapeutics Inc. (FHTX)vs › | $111.92M | -175.78% | -311.79% | -369.50% | -4193.27% |
| BGM Group Ltd. (BGM)vs › | $117.36M | -52.59% | -29.17% | -18.36% | -9.63% |
| LENZ Therapeutics, Inc. (LENZ)vs › | $117.50M | -586.74% | -215.13% | -125.58% | -83.72% |
Operating Margin
-415175.0%
Net Profit Margin
-422412.5%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | -115587.50% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | -98125.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | -6096.47% |
| 2022-12-31 | -5139.71% |
| 2022-09-30 | 44.63% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
